BR112018008103A2 - análogos de celastrol - Google Patents

análogos de celastrol

Info

Publication number
BR112018008103A2
BR112018008103A2 BR112018008103-5A BR112018008103A BR112018008103A2 BR 112018008103 A2 BR112018008103 A2 BR 112018008103A2 BR 112018008103 A BR112018008103 A BR 112018008103A BR 112018008103 A2 BR112018008103 A2 BR 112018008103A2
Authority
BR
Brazil
Prior art keywords
celastrol analogs
celastrol
analogs
compositions
treating
Prior art date
Application number
BR112018008103-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Mazitschek Ralph
Ding Yanbing
Shen Kaisheng
Original Assignee
Erx Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erx Pharmaceuticals, Inc. filed Critical Erx Pharmaceuticals, Inc.
Publication of BR112018008103A2 publication Critical patent/BR112018008103A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Liquid Crystal (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Optical Filters (AREA)
BR112018008103-5A 2015-10-23 2016-10-21 análogos de celastrol BR112018008103A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562245356P 2015-10-23 2015-10-23
US62/245,356 2015-10-23
PCT/US2016/058313 WO2017070615A1 (en) 2015-10-23 2016-10-21 Analogs of celastrol

Publications (1)

Publication Number Publication Date
BR112018008103A2 true BR112018008103A2 (pt) 2018-11-06

Family

ID=58558149

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018008103-5A BR112018008103A2 (pt) 2015-10-23 2016-10-21 análogos de celastrol

Country Status (8)

Country Link
US (3) US10662218B2 (cg-RX-API-DMAC7.html)
EP (1) EP3364956A4 (cg-RX-API-DMAC7.html)
JP (3) JP7034078B2 (cg-RX-API-DMAC7.html)
CN (2) CN119241632A (cg-RX-API-DMAC7.html)
AU (3) AU2016342375B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018008103A2 (cg-RX-API-DMAC7.html)
MA (1) MA45430A (cg-RX-API-DMAC7.html)
WO (1) WO2017070615A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119241632A (zh) * 2015-10-23 2025-01-03 Erx制药股份有限公司 雷公藤红素的类似物
WO2017180998A2 (en) 2016-04-15 2017-10-19 Beckman Coulter, Inc. Photoactive macromolecules and uses thereof
WO2017214709A1 (en) * 2016-06-15 2017-12-21 NOISEUX, Nicolas Reagents, compositions and methods for improving viability and function of cells, tissues and organs
CN108026142B (zh) * 2016-07-04 2022-07-08 艾凯奇(厦门)生物科技有限公司 孤儿核受体Nur77的配体及其用途
CN109705187B (zh) * 2019-01-29 2021-08-20 石家庄学院 一种雷公藤红素衍生物及其制备方法与应用
CN112094313B (zh) * 2019-06-17 2023-07-04 中国科学院上海药物研究所 一类氨基取代的雷公藤红素衍生物以及其制备方法和用途
CN112110977B (zh) * 2019-06-21 2022-02-25 中国科学院上海药物研究所 一类雷公藤红素衍生物、其制备方法及用途
CA3163593A1 (en) 2020-01-15 2021-07-22 Guangrong Zheng Therapeutic agents and methods of treatment
CN111202737B (zh) * 2020-03-20 2022-08-05 中国药科大学 雷公藤红素酰胺衍生物在制备治疗自身性免疫疾病药物的应用
US12673106B2 (en) 2020-08-28 2026-07-07 University Of Florida Research Foundation, Incorporated Modulators of nuclear receptor subfamily 4 group A member 1 (NR4A1) and uses thereof
CN115677812B (zh) * 2022-01-18 2023-12-15 聊城大学 一类雷公藤红素衍生物及其制备方法与应用
US20250375401A1 (en) * 2022-06-21 2025-12-11 Seoul National University R&Db Foundation Pharmaceutical composition containing demethylzeylasteral for prevention or treatment of diseases caused by muscle loss
IL317983A (en) * 2022-07-15 2025-02-01 Celloram Inc History of Celestrol
EP4618998A1 (en) * 2022-11-17 2025-09-24 ERX Pharmaceuticals Inc. Celastrol salts, crystalline forms, and uses thereof
US20260191807A1 (en) * 2022-11-17 2026-07-09 Erx Pharmaceuticals Inc. Compositions and methods for treatment of prader-willi syndrome
WO2025106760A1 (en) * 2023-11-16 2025-05-22 Erx Pharmaceuticals Corporation Intranasal formulations of celastrol
CN119431489A (zh) * 2024-11-13 2025-02-14 肇源县总医院 一种雷公藤红素衍生物及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US20030027786A1 (en) 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
FR2875913A1 (fr) 2004-09-29 2006-03-31 Sea On Line Sa Systeme d'alerte anti-collision installe a bord d'un vehicule marin et procede d'analyse anti-collision
ES2277568B1 (es) 2005-12-30 2008-04-01 Consejo Superior De Investigaciones Cientificas Derivados de triterpenoquinona y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias.
WO2007117466A2 (en) * 2006-03-31 2007-10-18 Massachusetts Institute Of Technology Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors
CN101686951A (zh) 2006-11-13 2010-03-31 纽约市哥伦比亚大学托管会 治疗糖尿病的选择性蛋白酶体抑制物
WO2009026163A1 (en) 2007-08-17 2009-02-26 Burnham Institute For Medical Research Compositions and methods for inhibiting growth and metastasis of melanoma
CA2808359C (en) * 2010-08-23 2019-09-24 Suzhou Neupharma Co., Ltd. Analogs of celasterol and pharmaceutical compositions comprised thereof
EA201492184A1 (ru) 2012-05-25 2015-07-30 Берг Ллк Способы лечения метаболического синдрома путем модулирования белка теплового шока (hsp) 90-бета
CA2874631C (en) 2012-05-25 2022-08-30 S.P.M. Flow Control, Inc. Apparatus and methods for evaluating systems associated with wellheads
CN111529535A (zh) * 2012-09-27 2020-08-14 儿童医学中心公司 用于治疗肥胖症的化合物和其使用方法
BR112016021985B1 (pt) * 2014-03-26 2022-08-30 The General Hospital Corporation Formulação farmacêutica
CN119241632A (zh) * 2015-10-23 2025-01-03 Erx制药股份有限公司 雷公藤红素的类似物
WO2018125812A1 (en) 2017-01-02 2018-07-05 Gauss Surgical, Inc. Tracking surgical items with prediction of duplicate imaging of items

Also Published As

Publication number Publication date
RU2018118633A (ru) 2019-11-25
US20240190911A1 (en) 2024-06-13
JP2022017473A (ja) 2022-01-25
MA45430A (fr) 2019-05-01
JP7339992B2 (ja) 2023-09-06
CN108601751A (zh) 2018-09-28
US20210061851A1 (en) 2021-03-04
AU2024201504A1 (en) 2024-03-28
AU2022204238A1 (en) 2022-07-07
JP7034078B2 (ja) 2022-03-11
JP2023164877A (ja) 2023-11-14
EP3364956A4 (en) 2019-05-01
JP2018531289A (ja) 2018-10-25
US10662218B2 (en) 2020-05-26
WO2017070615A1 (en) 2017-04-27
AU2022204238B2 (en) 2023-12-14
US20180362575A1 (en) 2018-12-20
AU2016342375B2 (en) 2022-03-17
CA3002924A1 (en) 2017-04-27
RU2018118633A3 (cg-RX-API-DMAC7.html) 2020-02-17
CN119241632A (zh) 2025-01-03
EP3364956A1 (en) 2018-08-29
US11753436B2 (en) 2023-09-12
AU2016342375A1 (en) 2018-05-17

Similar Documents

Publication Publication Date Title
BR112018010089A2 (pt) composições compreendendo cepas bacterianas
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
UY37036A (es) Compuestos inhibidores de la quinasa de unión a tank
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
BR112016006319A2 (pt) inibidores de irak e usos dos mesmos
LT3594238T (lt) Antikūno kompozicijos, skirtos navikų gydymui
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
BR112016022658A2 (pt) anticorpos anti-ox40 e métodos de uso
EP4193993A3 (en) Combinations of cannabinoids and n-acylethanolamines
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
BR112017007414A2 (pt) combinações compreendendo siponimod e laquinimod para o tratamento de esclerose múltipla
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
BR112017011168A2 (pt) medicamentos para retardar a doença de parkinson
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.
PT3551619T (pt) Composições compreendendo profármacos de metilfenidato, processos de preparação e utilização dos mesmos
BR112017018834A2 (pt) variantes de protoxina-ii e métodos de uso
BR112017009000A2 (pt) apilimod para uso no tratamento de melanoma
BR112017021194A2 (pt) compostos espirocíclicos
BR112019023742A2 (pt) anticorpos anti-trkb
BR112017000303A2 (pt) métodos para o tratamento de hipotensão
MX374654B (es) Compuestos útiles para inhibir ror-gamma-t.
BR112017011685A2 (pt) composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas
BR112017002852A2 (pt) compostos de azetidiniloxifenilpirrolidina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023014342-6 PROTOCOLO 870230062644 EM 17/07/2023 17:57.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2854 DE 16-09-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.